Exploring Beta-Lactam Combination Agents: Opportunities, Gaps, and Challenges
Please register for this course to claim P.A.C.E. credits from the June Education Session and access the on-demand recording.
Explore the challenges and successes of using beta-lactam combination agents from three different perspectives, including the pharmaceutical industry, the laboratory, and clinical practice. This session will delve into the development process of beta-lactam combination agents and laboratory requests and QC issues. The successes and failures of using beta-lactam combination agents in clinical practice will also be discussed.
Learning Objectives
- Describe the process in development of beta-lactam combination agents.
- Recognize requests that laboratories receive for testing these agents.
- Identify challenges laboratories face with QC issues when testing beta-lactam combination agents.
- Summarize the success and failures of using beta-lactam combination agents in clinical practice.
Clinical and Laboratory Standards Institute is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program.
Romney Humphries, PhD D(ABMM)
Professor, Department of Pathology, Microbiology and Immunology
Vanderbilt University Medical Center
Romney Humphries, PhD D(ABMM) is a Professor in the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center, where she is the Director of Infectious Diseases Laboratories and the Director of the Division of Laboratory Medicine. Romney received her PhD in bacteriology from the University of Calgary, Canada and a clinical and public health microbiology CPEP fellowship at UCLA.
Dr. Humphries is passionate about clinical microbiology and antimicrobial resistance in particular. She is a champion for the development of novel diagnostic tests for infectious diseases to transform how patients with infections are managed.
Greg Moeck, PhD
Senior Vice President, Microbiology
Venatorx Pharmaceuticals, Inc.
Dr. Moeck is Senior Vice President, Microbiology at Venatorx Pharmaceuticals where he is responsible for ensuring comprehensive and timely characterization of investigational agents via clinical microbiology studies. He has spent over 15 years in antibacterial drug discovery and development, leading cross-functional teams or as a team member advancing the long-acting lipoglycopeptide oritavancin through nonclinical IND-enabling studies. Dr. Moeck has published over 50 papers in peer-reviewed journals, co-authored three book chapters, and is co-inventor on four patents relating to methods of treatment of bacterial infections.
Andrew Fratoni, PharmD
Associate Director, Clinical and Laboratory Studies
Hartford Hospital
Dr. Fratoni is the Associate Director of Clinical and Laboratory Studies at Hartford Hospital in Hartford, CT.
Key:
Complete
Next
Failed
Available
Locked